Clinical trial
Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study
NCT06291025 is registered in ClinicalTrials.gov with University Hospital, Rouen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study
- Lead sponsor
- University Hospital, Rouen
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- April 10, 2024
- Completion date
- August 1, 2026
- Enrollment
- 131 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.